Tacrine inhibits topoisomerases and DNA synthesis to cause mitochondrial DNA depletion and apoptosis in mouse liver

Hepatology

Volumn 38, Issue 3, 2003, Pages 715-725

  Mansouri, Abdellah ^b   Haouzi, Delphine ^b   Descatoire, Véronique ^b   Demeilliers, Christine ^b   Sutton, Angela ^b   Vadrot, Nathalie ^b   Fromenty, Bernard ^b   Feldmann, Gérard ^b   Pessayre, Dominique ^b   Berson, Alain ^a  

^a INSERM   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CASPASE 3; CELL NUCLEUS DNA; CYTOCHROME C; DNA; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); MITOCHONDRIAL DNA; PROTEIN BAX; PROTEIN P53; TACRINE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; DNA REPLICATION; DNA SUPERCOILING; DNA SYNTHESIS INHIBITION; DRUG MECHANISM; ENZYME INHIBITION; IN VITRO STUDY; LIVER CELL; LIVER TOXICITY; MALE; MEMBRANE PERMEABILITY; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL RESPIRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0041822082     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2003.50353     Document Type: Article

References (44)

1. Hebert LE, Scherr PA, Beckett LA, Albert MS, Pilgrim DM, Chown MJ, Funkestein HH, et al. Age-specific incidence of Alzheimer's disease in a community population. JAMA 1995;273:1354-1359.
2. Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR. Alzheimer's disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981;10:122-126.
3. Davis KL, Thal LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, Drachman DA, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med 1992;327:1253-1259.
4. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994;271:992-998.
5. Hammel P, Larrey D, Bernuau J, Kalafat M, Fréneaux E, Babany G, Degott C, et al. Acute hepatitis after tetrahydroaminoacridine administration for Alzheimer's disease. J Clin Gastroenterol 1990;12:329-331.
6. Farris MW, Johnsen SA, Walton LP, Mumaw VR, Ray SD. Tetrahydroaminoacridine-induced ribosomal changes and inhibition of protein synthesis in rat hepatocyte suspension. HEPATOLOGY 1994;20:240-246.
7. Berson A, Renault S, Lettéron P, Robin MA, Fromenty B, Fau D, Le Bot MA, et al. Uncoupling of rat and human mitochondria: a possible explanation for tacrine-induced liver dysfunction. Gastroenterology 1996;110:1878-1890.
8. Woolf TF, Pool WF, Bjorge SM, Chang T, Goel OP, Purchase II CF, Schroeder MC, et al. Bioactivation and irreversible binding of the cognition activator tacrine using human and rat liver microsomal preparations. Species difference. Drug Metab Dispos 1993;21:874-882.
9. Viau CJ, Curren RD, Wallace K. Cytotoxicity of tacrine and velnacrine metabolites in cultured rat, dog and human hepatocytes. Drug Chem Toxicol 1993;16:227-239.
10. Fontana RJ, Turgeon DK, Woolf TF, Knapp MA, Foster NL, Watkins PB. The caffeine breath test does not identify patients susceptible to tacrine hepatotocicity. HEPATOLOGY 1996;23:1429-1435.
11. Green VJ, Pirmohamed M, Kitteringham NR, Knapp MJ, Park BK. Glutathione S-transferase μ genotype (GSTM1*0) in Alzheimer's patients with tacrine transaminitis. Br J Clin Pharmacol 1995;39:411-415.
12. Plymale DR, de la lglesia FA. Acridine-induced subcellular and functional changes in isolated human hepatocytes in vitro. J Appl Toxicol 1999;19:31-38.
13. Robertson RG, Braden TK, Urda ER, Lalwani ND, de la Iglesia FA. Elucidation of the mitochondrial effects by tetraminoacridine (tacrine) in rat, dog, monkey and human hepatic parenchymal cells. Arch Toxicol 1998;72:362-371.
14. Crenshaw JM, Graves DE, Denny WA. Interactions of acridine antitumor agents with DNA: binding energies and groove preferences. Biochemistry 1995;34:13682-13687.
15. Nelson EM, Tewey KM, Liu LF. Mechanism of antitumor drug action: poisoning of mammalian DNA polymerase II on DNA by 4'-(9-acridinylamino)-methanesulfon-m-anisidide. Proc Natl Acad Sci U S A 1984;81:1361-1365.
16. Skaladanowski A, Plisov SY, Konopa J, Larsen AK. Inhibition of DNA topoisomerase II by imidazoacridinones, new antineoplastic agents with strong activity against solid tumors. Mol Pharmacol 1996;49:772-780.
17. Freudenreich CH, Kreuzer KN. Localization of an aminoacridine antitumor agent in a type II topoisomerase-DNA complex. Proc Natl Acad Sci U S A 1994;91:11007-11011.
18. Ferguson LR. Inhibitors of topoisomerase II enzymes: a unique group of environmental mutagens and carcinogens. Mutat Res 1998;400:271-278.
19. Zeiger E, Erexson G, Mortelmans K, Thilagar A. Genetic toxicity studies of 1,2,3,4-tetrahydro-9-acridinamine (tacrine). Mutat Res 1997;393:189-197.
20. Lin J-H, Castora FJ. DNA topoisomerase II from mammalian mitochondria is inhibited by the antitumor drugs, m-AMSA and VM-26. Biochem Biophys Res Commun 1991;176:690-697.
21. Lawrence JW, Darkin-Rattray S, Xie F, Neims AH, Rowe TC. 4-Quinolones cause a selective loss of mitochondrial DNA from mouse L1210 leukemia cells. J Cell Biochem 1993;51:165-174.
22. Lawrence JW, Claire DC, Weissig V, Rowe TC. Delayed cytotoxicity and cleavage of mitochondrial DNA in ciprofloxacin-treated mammalian cells. Mol Pharmacol 1996;50:1178-1188.
23. Li T-K, Liu LF. Tumor cell death induced by topoisomerase-targeting drugs. Annu Rev Pharmacol Toxicol 2001;41:53-77.
24. Karpinich NO, Tafani M, Rothman RJ, Russo MA, Farber JL. The course of etoposide-induced apoptosis from damage to DNA and p53 activation to mitochondrial release of cytochrome c. J Biol Chem 2002;277:1647-16552.
25. Zhang H, Barceló JM, Lee B, Kohlhagen G, Zimonjic DB, Popescu NC, Pommier Y. Human mitochondrial topoisomerase I. Proc Natl Acad Sci U S A 2001;98:1068-10613.
26. Demeilliers C, Maisonneuve C, Grodet A, Mansouri A, Ngyuen R, Tinel M, Lettéron P, et al. Impaired adaptive resynthesis and prolonged depletion of hepatic mitochondrial DNA after repeated alcohol binges in mice. Gastroenterology 2002;123:1278-1290.
27. Mansouri A, Gaou I, de Kerguence C, Amsellem S, Haouzi D, Berson A, Moreau A, et al. An alcoholic binge causes massive degradation of hepatic mitochondrial DNA in mice. Gastroenterology 1999;117:181-190.
28. Fau D, Berson A, Eugène D, Fromenty B, Fisch C, Pessayre D. Mechanism for the hepatotoxicity of the anti-androgen, nilutamide. Evidence suggesting that redox cycling of this nitroaromatic drug leads to oxidative stress in isolated hepatocytes. J Pharmacol Exp Ther 1992;263:69-77.
29. Sutton A, Khoury H, Prip-Buus C, Cepanec C, Pessayre D, Degoul F. The Ala-9Val dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria. Pharmacogenetics 2003;13:145-157.
30. Haouzi D, Lekehal M, Moreau A, Moulis G, Feldmann G, Robin MA, Lettéron P, et al. Cytochrome P450-generated reactive metabolites cause mitochondrial permeability transition, caspase activation and apoptosis in rat hepatocytes. HEPATOLOGY 2000;32:303-311.
31. Feldmann G, Haouzi D, Moreau A, Durand-Schneider AM, Bringuier A, Berson A, Mansouri A, et al. Opening of the mitochondrial permeability transition pore causes matrix expansion and outer membrane rupture in Fas-mediated hepatic apoptosis in mice. HEPATOLOGY 2000;31:674-683.
32. Haouzi D, Lekehal M, Tinel M, Vadrot N, Caussanel L, Lettéron P, Moreau A, et al. Prolonged, but not acute, glutathione depletion promotes Fas-mediated mitochondrial permeability transition and apoptosis in mice. HEPATOLOGY 2001;33:1181-1188.
33. Rowe TC, Weissig V, Lawrence JW. Mitochondrial DNA metabolism targeting drugs. Adv Drug Deliv Rev 2001;49:175-187.
34. Fromenty B, Pessayre D. Inhibition of mitochondrial β-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther 1995;67:101-154.
35. Capano M, Crompton M. Biphasic translocation of Bax to mitochondria. Biochem J 2002;367:169-178.
36. Shimizu S, Narita M, Tsujimoto Y. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 1999;399:483-487.
37. Pastorino JG, Chen S-T, Tafani M, Snyder JW, Farber JL. The overexpression of Bax produces cell death upon induction of the mitochondrial permeability transition. J Biol Chem 1998;273:7770-7775.
38. Nechushtan A, Smith CL, Lamensdorf I, Yoon SH, Youle RJ. Bax and Bak coalesce into novel mitochondria-associated clusters during apoptosis. J Cell Biol 2001;153:1265-1276.
39. 2+ stores. J Biol Chem 2002;277:9219-9225.
40. Narita M, Shimizu S, Ito T, Chittenden T, Lutz RJ, Matsuda H, Tsujimoto Y. Bax interacts with the permeability transition pore to induce permeability transition and cytochrome c release in isolated mitochondria. Proc Natl Acad Sci U S A 1998;95:14681-14686.
41. Leist M, Single B, Castoldi AF, Kühnle S, Nicotera P. Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J Exp Med 1997;185:1481-1486.
42. Diehl AM, Rai RM. Regulation of signal transduction during liver regeneration. FASEB J 1996;10:215-227.
43. Bissel DM, Gores GJ, Laskin DL, Hoofnagle JH. Drug-induced liver injury: mechanisms and test systems. HEPATOLOGY 2001;33:1009-1013.
44. Gaou I, Malliti M, Guimont MC, Lettéron P, Demeilliers C, Peytavin G, Degott C, et al. Effect of stavudine on mitochondrial genome and fatty acid oxidation in lean and obese mice. J Pharmacol Exp Ther 2001;297:516-523.